



# VettaFi Weight Loss Drug & Treatment Index

## THINR

### Table of Contents

Introduction .....	2
Index Objective .....	2
Highlights .....	2
Dates .....	2
Supporting Documents .....	2
Eligibility Criteria and Index Construction .....	3
Universe .....	3
Index Construction .....	3
Constituent Selection .....	3
Constituent Weightings & Constraints .....	3
Index Maintenance .....	4
Rebalancing and Reconstitution .....	4
Corporate Actions .....	4
Index Information .....	4
Index Calculation .....	4
Index Governance .....	4
Index Policies .....	4
Contact Information .....	5

## Introduction

### Index Objective

The VettaFi Weight Loss Drug Index is an index of global companies who are manufacturers in the GLP-1 pharmaceuticals business or who enable the business. The index allocates 70% of its weight to a Principal Manufacturers segment and 30% to an Enablers segment.

### Highlights

The Manufacturers segment includes companies that have launched production or are in FDA clinical trials.

The Enablers segment includes companies active in outsourced work or other work that is a component of the GLP-1 market.

### Dates

Reference Dates: Last Business Date of month prior to Rebalance/Reconstitution Month.

Reconstitution Dates: Indexes reconstituted quarterly on the third Friday of the last month of each calendar quarter.

Weight Date: Thursday prior to second Friday of Rebalance/Reconstitution Month.

Rebalance Dates: Indexes are rebalanced quarterly on the third Friday of the last month of each calendar quarter.

## Supporting Documents

This methodology is meant to be read in conjunction with supporting documents providing greater detail with respect to the policies, procedures and calculations described herein.

The list of the main supplemental documents for this methodology can be found in the Methodologies and Governance tabs on the [Index Resources](#) page as follows:

Supporting Documents
Index Maintenance Policy
Index Governance
Index Policies
Methodology Policies
Glossary
Index Change and Consultation Policy

## Eligibility Criteria and Index Construction

### Universe

Constituents of the S-Network Developed World Equity 5000 Index (SNDW5K) or the VettaFi Developed World Index (VFDW).

## Index Construction

### Constituent Selection

A company must be classified as a Drug Manufacturer or as an Enabler based on the following criteria:

Drug Manufacturers:

Companies with GLP-1 Agonist Drugs that are either launched or are in FDA clinical trials.

Enablers:

Companies involved with the outsourced development and manufacturing of GLP-1 Agonist Drugs. This includes companies conducting measurement and analysis or other work that supports GLP-1 Agonist production and distribution.

Additionally, companies must meet the following criteria:

- Minimum Company Market Cap – 500 million USD

### Constituent Weightings & Constraints

Weights are float market cap weighted within their segment allocation.

Drug Manufacturer Segment:

- 70% weight allocation
- Constituent caps
  - Companies at commercial or phase 3 stage: constituents capped at 15%
  - Companies at phase 2 or lower stage: constituents capped at 5%

Enabler Segment:

- 30% weight allocation
- Constituent caps
  - Constituents capped at 5%

Additionally, the sum of all constituent weights greater than 5% must be less than or equal to 45% of the total index. Capped weights are redistributed within their segment.

## Index Maintenance

### Rebalancing and Reconstitution

The Indexes are rebalanced on the “Rebalance Date” and additionally reconstituted on the “Reconstitution Date”. Pricing used in share weights used for reconstitutions are as of the “Weight Date”. Share weights for the rebalanced Indexes are computed as of the “Weight Date”. Changes to the Indexes related to the rebalances are as of the “Rebalance Date”. Additions are only made on reconstitution dates.

### Corporate Actions

Please refer to the Index Maintenance Policy document for information on Corporate Action processing.

### Index Information

Index history availability, base dates and base values are shown in the table below.

Index	Price Index	Base Date	Base Value	Total Return Index	Base Date	Base Value
VettaFi Weight Loss Drug & Treatment Index	THINR	06/18/21	1000	THINRT	06/18/21	1000

### Methodology Updates and Changes

Date	Version	Previous	New
Apr 2024	1.0.1	Name: VettaFi Weight Loss Drug Index	VettaFi Weight Loss Drug & Treatment Index

## Index Calculation

Please refer to the Index Maintenance Policy document for information on index calculations.

## Index Governance

The index is governed and managed by a VettaFi Index Committee for the purpose of meeting the goals of the index. For more information, please refer to the Index Governance document.

## Index Policies

Please refer to the Index Policies document for information regarding Announcements, Holiday Schedules, Unexpected Exchange Closures, and Recalculation Policy.

## Contact Information

For any questions regarding an index, please contact: [index.production@vettafi.com](mailto:index.production@vettafi.com)